NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free PODD Stock Alerts $171.40 +2.22 (+1.31%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$169.22▼$172.2150-Day Range$163.60▼$206.0352-Week Range$125.82▼$335.91Volume786,601 shsAverage Volume914,867 shsMarket Capitalization$11.99 billionP/E Ratio58.90Dividend YieldN/APrice Target$250.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Insulet alerts: Email Address Insulet MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.81 Rating ScoreUpside/Downside46.1% Upside$250.33 Price TargetShort InterestHealthy4.00% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.89Based on 5 Articles This WeekInsider TradingSelling Shares$1.89 M Sold Last QuarterProj. Earnings Growth25.65%From $3.08 to $3.87 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.89 out of 5 starsMedical Sector40th out of 938 stocksSurgical & Medical Instruments Industry6th out of 95 stocks 3.4 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $250.33, Insulet has a forecasted upside of 46.1% from its current price of $171.40.Amount of Analyst CoverageInsulet has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.00% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 4.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 3.3 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Insulet this week, compared to 8 articles on an average week.Search Interest13 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat Follows12 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,891,338.00 in company stock.Percentage Held by InsidersOnly 0.90% of the stock of Insulet is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 25.65% in the coming year, from $3.08 to $3.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 58.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 147.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 58.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 275.57.Price to Earnings Growth RatioInsulet has a PEG Ratio of 2.98. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 16.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Insulet Stock (NASDAQ:PODD)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PODD Stock News HeadlinesMarch 8, 2024 | marketbeat.comAre These 5 Undervalued Stocks Ready to Break Out?Albemarle Corp. NYSE: ALB, Ionis Pharmaceuticals Inc. NASDAQ: IONS, Insulet Corp. NASDAQ: PODD, Hess Corp. NYSE: HES and Wynn Resorts Ltd. NASDAQ: WYNN are among undervalued stocks that beat analysts earnings views.March 8, 2024 | marketbeat.comAre These 5 Undervalued Stocks Ready to Break Out? (PODD)Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.March 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 28, 2024 | finance.yahoo.comInvestors Will Want Insulet's (NASDAQ:PODD) Growth In ROCE To PersistMarch 28, 2024 | seekingalpha.comInsulet: Insulating Patients, Investors Still Have To WaitMarch 25, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Twilio, Zscaler, NextEra Energy, and American Water WorksMarch 21, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)March 20, 2024 | msn.comInsulet names Ana Maria Chadwick as finance chiefMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 20, 2024 | markets.businessinsider.comInsulet Names Ana Maria Chadwick CFO, Effective April 22March 20, 2024 | businesswire.comInsulet Appoints Ana Maria Chadwick as Chief Financial OfficerMarch 19, 2024 | msn.comHere's Why Insulet (PODD) Detracted in Q4March 19, 2024 | finance.yahoo.comHere’s Why Insulet (PODD) Detracted in Q4March 19, 2024 | americanbankingnews.comInsulet Co. (NASDAQ:PODD) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarch 17, 2024 | finance.yahoo.comPODD Apr 2024 135.000 callMarch 16, 2024 | markets.businessinsider.comInsulet’s Growth Trajectory Affirmed with a Buy Rating and Revised Target PriceMarch 15, 2024 | finance.yahoo.comPODD Apr 2024 165.000 callMarch 15, 2024 | finance.yahoo.comPODD Apr 2024 190.000 putMarch 15, 2024 | finance.yahoo.comPODD Jan 2025 180.000 callMarch 11, 2024 | finance.yahoo.comCalculating The Fair Value Of Insulet Corporation (NASDAQ:PODD)March 8, 2024 | finance.yahoo.comInsulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump TherapyMarch 8, 2024 | businesswire.comInsulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump TherapyMarch 7, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD) and Adaptimmune Therapeutics (ADAP)March 5, 2024 | businesswire.comInsulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)March 5, 2024 | businesswire.comInsulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)March 4, 2024 | fool.comIs It Time to Buy the S&P 500's 3 Worst-Performing February Stocks?February 26, 2024 | markets.businessinsider.comInsulet’s Strong Growth and Market Position Justify Buy Rating Despite Short-Term Revenue Guidance ConcernsSee More Headlines Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$250.33 High Stock Price Target$350.00 Low Stock Price Target$184.00 Potential Upside/Downside+46.1%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$2.91 Trailing P/E Ratio58.90 Forward P/E Ratio55.65 P/E Growth2.98Net Income$206.30 million Net Margins12.16% Pretax Margin12.65% Return on Equity32.19% Return on Assets7.93% Debt Debt-to-Equity Ratio1.86 Current Ratio3.51 Quick Ratio2.62 Sales & Book Value Annual Sales$1.70 billion Price / Sales7.06 Cash Flow$3.93 per share Price / Cash Flow43.62 Book Value$10.49 per share Price / Book16.34Miscellaneous Outstanding Shares69,930,000Free Float69,297,000Market Cap$11.99 billion OptionableOptionable Beta0.98 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. James R. Hollingshead Ph.D. (Age 61)President, CEO & Director Comp: $2.18MMs. Shacey Petrovic (Age 50)Director & Advisor Comp: $2.96MMr. Eric Benjamin (Age 41)Executive VP, Chief Product & Customer Experience Officer Comp: $947.57kMs. Lauren BuddenGroup VP, Chief Accounting Officer, Controller & Interim CFO and TreasurerMr. Prem Singh (Age 47)Senior Vice President of Global Operations Mr. Mark FieldSenior VP & CTOMs. Deborah R. Gordon CPA (Age 54)Vice President of Investor Relations Mr. John Wodick Kapples (Age 64)Senior VP & General Counsel Comp: $783.36kMs. Laetitia Cousin (Age 48)Senior VP of Regulatory Affairs, Quality Assurance & Compliance Angela Geryak WiczekSenior Director of Corporate CommunicationsMore ExecutivesKey CompetitorsUnited TherapeuticsNASDAQ:UTHRSmith & NephewNYSE:SNNExact SciencesNASDAQ:EXASDaVitaNYSE:DVAUniversal Health ServicesNYSE:UHSView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 2,856 shares on 3/22/2024Ownership: 0.015%HBK Investments L PBought 7,500 shares on 3/14/2024Ownership: 0.000%Vanguard Group Inc.Bought 29,387 shares on 3/11/2024Ownership: 11.482%SageView Advisory Group LLCBought 1,088 shares on 3/6/2024Ownership: 0.002%Fisher Asset Management LLCSold 59,703 shares on 3/5/2024Ownership: 0.492%View All Insider TransactionsView All Institutional Transactions PODD Stock Analysis - Frequently Asked Questions Should I buy or sell Insulet stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price target for 2024? 16 equities research analysts have issued 12-month price targets for Insulet's stock. Their PODD share price targets range from $184.00 to $350.00. On average, they predict the company's share price to reach $250.33 in the next year. This suggests a possible upside of 46.1% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2024? Insulet's stock was trading at $216.98 at the start of the year. Since then, PODD stock has decreased by 21.0% and is now trading at $171.40. View the best growth stocks for 2024 here. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PODD earnings forecast. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Thursday, February, 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.73. The medical instruments supplier had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. Insulet had a trailing twelve-month return on equity of 32.19% and a net margin of 12.16%. The business's quarterly revenue was up 37.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.55 EPS. What ETFs hold Insulet's stock? ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Focused Discovery Growth ETF (IVDG), Harbor Health Care ETF (MEDI), VictoryShares Nasdaq Next 50 ETF (QQQN), Nuveen ESG Mid-Cap Growth ETF (NUMG) and Fidelity Disruptive Medicine ETF (FMED). What guidance has Insulet issued on next quarter's earnings? Insulet issued an update on its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $419.0 million-$429.7 million, compared to the consensus revenue estimate of $442.5 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). Who are Insulet's major shareholders? Insulet's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (13.57%), Vanguard Group Inc. (11.50%), Vanguard Group Inc. (11.48%), Capital World Investors (3.17%), Clearbridge Investments LLC (1.90%) and Baillie Gifford & Co. (1.74%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PODD) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.